The Biostatistics and Informatics Core for the Duke SPORE in Breast Cancer is intended to support the statistical and information systems needs of all projects and cores in the SPORE. The Core was developed in conjunction with the institute of Statistics and Decision Sciences and Cancer Center Information Systems. The Biostatistics and Informatics Core makes use of Cancer Center Core resources to support statistical and informatics needs. Dr. Donald Berry, Professor the Institute of Statistics and Decision Sciences and statistician for the Cancer and Leukemia Group B (CALGB) Breast Cancer Committee, and Kimberly Johnson, Director of Cancer Center Information Systems are managers of this Core. Additional staff for this Core include Gloria Broadwater, Staff Statistician, Mark Peedlin, Lead Programmer, and Sunil Kishnani, Database Administrator. This Core will provide support in the design statistical analysis of basic and clinical scientific studies for Projects 1-6 and Cores 1 and 4. Databases have been developed to support Cores 1 and 4, and Projects 2, 3 and 6. Additional programming support is provided to project 4. All databases reside on a WindowNT SQL Server provided and maintained by Cancer Center Information Systems. Enhancements to existing databases will continue and the development of interfaces between various databases related to the SPORE will be a primary goal for this Core.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA068438-05S1
Application #
6356518
Study Section
Project Start
2000-09-22
Project End
2003-08-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
5
Fiscal Year
2000
Total Cost
$179,222
Indirect Cost
Name
Duke University
Department
Type
DUNS #
071723621
City
Durham
State
NC
Country
United States
Zip Code
27705
Osada, Takuya; Hartman, Zachary C; Wei, Junping et al. (2018) Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers. Breast Cancer Res 20:90
Goncalves, Rodrigo; DeSchryver, Katherine; Ma, Cynthia et al. (2017) Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer. Breast Cancer Res Treat 165:355-364
Mertins, Philipp; Yang, Feng; Liu, Tao et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13:1690-704
Li, Shunqiang; Shen, Dong; Shao, Jieya et al. (2013) Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep 4:1116-30
Cao, Yiting; Eble, Joseph M; Moon, Ejung et al. (2013) Tumor cells upregulate normoxic HIF-1? in response to doxorubicin. Cancer Res 73:6230-42
Aird, Katherine M; Allensworth, Jennifer L; Batinic-Haberle, Ines et al. (2012) ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells. Breast Cancer Res Treat 132:109-19
Ellis, Matthew J; Ding, Li; Shen, Dong et al. (2012) Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486:353-60
D'Amato, Nicholas C; Ostrander, Julie H; Bowie, Michelle L et al. (2012) Evidence for phenotypic plasticity in aggressive triple-negative breast cancer: human biology is recapitulated by a novel model system. PLoS One 7:e45684
Il'yasova, Dora; Kennedy, Kelly; Spasojevic, Ivan et al. (2011) Individual responses to chemotherapy-induced oxidative stress. Breast Cancer Res Treat 125:583-9
Ye, Xiaodong; Fels, Diane; Tovmasyan, Artak et al. (2011) Cytotoxic effects of Mn(III) N-alkylpyridylporphyrins in the presence of cellular reductant, ascorbate. Free Radic Res 45:1289-306

Showing the most recent 10 out of 103 publications